Global Topical Drug Delivery Market - Trends and Forecast to 2024
Synopsis:
Global Topical Drug Delivery Market is expected to reach USD 194.2 billion by 2024, at a CAGR 9.3% during the forecast period of 2017 to 2024. The report contains 300 pages of exclusive premium insights with 290 tables and 25 figures.
Topical drug delivery involves the introduction of a medication to the body surface such as skin or mucous membrane or to the circulatory system by periodic transdermal drug delivery for the treatment of diseases. It is considered as key route for local and systemic treatment. Drugs delivered through this route of administration penetrate deeply into the skin and are better absorbed. Topical drugs such as sunscreens and astringents are used for prophylaxis. They are used in the treatment of skin conditions such as bacterial, fungal, and viral infections; inflammation; pruritus; corns; warts; and other dermatologic conditions. Also products such as transdermal patches provide systemic drug delivery non-invasively. Topical drug delivery includes liquid, semi-solid, solid, and transdermal patches and gels.
The global topical drug delivery market have been segmented On the basis of product type into transdermal drug delivery device and topical drug delivery formulation. Transdermal drug delivery devices market is segmented into patches and, gels. The topical drug delivery formulation is segmented into liquid, semi-solid, solid.
Based on end-user the market is segmented into hospitals, clinics, home healthcare, diagnostic centers and others.
On the basis of distribution channel the market is segmented into hospital pharmacy, pharmacy stores, direct tender and online pharmacy.
Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29 major countries such as United States of America, Canada, Mexico, Germany, France, United Kingdom, Italy, Spain, Switzerland, Netherlands, Turkey, Belgium, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Thailand, Malaysia, Singapore, Philippines, Indonesia, Rest of APAC, Brazil, Rest of South America, South Africa and Rest of MEA.
Major Players Operating in this market:
MedPharm, Janssen Pharmaceuticals, Inc. (A J&J Company), Crescita Therapeutics, West Pharmaceutical Services, Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., and Solvay among others.
Regions Covered In The Scope Of The Report:
Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa (South Africa, Rest of MEA))
Global Topical Drug Delivery Market is expected to reach USD 194.2 billion by 2024, at a CAGR 9.3% during the forecast period of 2017 to 2024. The report contains 300 pages of exclusive premium insights with 290 tables and 25 figures.
Topical drug delivery involves the introduction of a medication to the body surface such as skin or mucous membrane or to the circulatory system by periodic transdermal drug delivery for the treatment of diseases. It is considered as key route for local and systemic treatment. Drugs delivered through this route of administration penetrate deeply into the skin and are better absorbed. Topical drugs such as sunscreens and astringents are used for prophylaxis. They are used in the treatment of skin conditions such as bacterial, fungal, and viral infections; inflammation; pruritus; corns; warts; and other dermatologic conditions. Also products such as transdermal patches provide systemic drug delivery non-invasively. Topical drug delivery includes liquid, semi-solid, solid, and transdermal patches and gels.
The global topical drug delivery market have been segmented On the basis of product type into transdermal drug delivery device and topical drug delivery formulation. Transdermal drug delivery devices market is segmented into patches and, gels. The topical drug delivery formulation is segmented into liquid, semi-solid, solid.
Based on end-user the market is segmented into hospitals, clinics, home healthcare, diagnostic centers and others.
On the basis of distribution channel the market is segmented into hospital pharmacy, pharmacy stores, direct tender and online pharmacy.
Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29 major countries such as United States of America, Canada, Mexico, Germany, France, United Kingdom, Italy, Spain, Switzerland, Netherlands, Turkey, Belgium, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Thailand, Malaysia, Singapore, Philippines, Indonesia, Rest of APAC, Brazil, Rest of South America, South Africa and Rest of MEA.
Major Players Operating in this market:
MedPharm, Janssen Pharmaceuticals, Inc. (A J&J Company), Crescita Therapeutics, West Pharmaceutical Services, Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., and Solvay among others.
Regions Covered In The Scope Of The Report:
Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa (South Africa, Rest of MEA))
1 INTRODUCTION
1.1. OVERVIEW OF THE GLOBAL TOPICAL DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL TOPICAL DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. GLOBAL TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
4.3.1.2. GROWTH IN TRANSDERMAL TECHNOLOGY
4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 EXECUTIVE SUMMARY
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
6.2.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.2.1.1. TRANSDERMAL PATCHES
6.2.1.2. TRANSDERMAL GELS
6.2.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.2.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.1.1. SOLUTIONS
6.2.2.1.2. SUSPENSIONS
6.2.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.2.1. GELS
6.2.2.2.2. CREAMS
6.2.2.2.3. OINTMENTS
6.2.2.2.4. PASTES
6.2.2.2.5. LOTIONS
6.2.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.3.1. SUPPOSITORIES
6.2.2.3.2. POWDERS
7 TOPICAL DRUG DELIVERY MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. HOME HEALTHCARE
7.4. CLINICS
7.5. DIAGNOSTIC CENTERS
7.6. OTHERS
8 TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. HOSPITAL PHARMACIES
8.3. PHARMACY STORES
8.4. DIRECT TENDERS
8.5. ONLINE PHARMACY
9 TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.6. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.10. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11 TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES
11.1 JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY)
11.1.1 COMPANY OVERVIEW
11.1.2 SWOT ANALYSIS
11.1.3 REVENUE ANALYSIS
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPEMENTS
11.1.5 DATA BRIDGE ANALYSIS
11.2 CRESCITA THERAPEUTICS
11.2.1 COMPANY OVERVIEW
11.2.2 SWOT ANALYSIS
11.2.3 REVENUE ANALYSIS
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPEMENTS
11.2.5 DATA BRIDGE ANALYSIS
11.3 GALDERMA S.A.
11.3.1 COMPANY OVERVIEW
11.3.2 SWOT ANALYSIS
11.3.3 REVENUE ANALYSIS
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPEMENTS
11.3.5 DATA BRIDGE ANALYSIS
11.4 BIOFARMITALIA S.R.L
11.4.1 COMPANY OVERVIEW
11.4.2 SWOT ANALYSIS
11.4.3 REVENUE ANALYSIS
11.4.4 PRODUCT PORTFOLIO
11.4.5 RECENT DEVELOPEMENTS
11.4.5 DATA BRIDGE ANALYSIS
11.5 PHARMATEK LABORATORIES, INC.
11.5.1 COMPANY OVERVIEW
11.5.2 SWOT ANALYSIS
11.5.3 REVENUE ANALYSIS
11.5.4 PRODUCT PORTFOLIO
11.5.5 RECENT DEVELOPEMENTS
11.5.5 DATA BRIDGE ANALYSIS
11.6 STIEFEL LABORATORIES, INC.
11.6.1 COMPANY OVERVIEW
11.6.2 SWOT ANALYSIS
11.6.3 REVENUE ANALYSIS
11.6.4 PRODUCT PORTFOLIO
11.6.5 RECENT DEVELOPEMENTS
11.6.5 DATA BRIDGE ANALYSIS
11.7 TAPEMARK
11.7.1 COMPANY OVERVIEW
11.7.2 SWOT ANALYSIS
11.7.3 REVENUE ANALYSIS
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPEMENTS
11.7.5 DATA BRIDGE ANALYSIS
11.8 NITTO DENKO CORPORATION
11.8.1 COMPANY OVERVIEW
11.8.2 SWOT ANALYSIS
11.8.3 REVENUE ANALYSIS
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPEMENTS
11.8.5 DATA BRIDGE ANALYSIS
11.9 VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 MYLAN PHARMACEUTICALS INC.
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 HISAMITSU PHARMACEUTICAL CO., INC.
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.10 THERASOLVE NV.
11.10.1 COMPANY OVERVIEW
11.10.2 SWOT ANALYSIS
11.10.3 REVENUE ANALYSIS
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPEMENTS
11.10.5 DATA BRIDGE ANALYSIS
11.11 SAMYANG BIOPHARMACEUTICALS CORPORATION
11.11.1 COMPANY OVERVIEW
11.11.2 SWOT ANALYSIS
11.11.3 REVENUE ANALYSIS
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPEMENTS
11.11.5 DATA BRIDGE ANALYSIS
11.12 LOHMANN THERAPIE-SYSTEME AG
11.12.1 COMPANY OVERVIEW
11.12.2 SWOT ANALYSIS
11.12.3 REVENUE ANALYSIS
11.12.4 PRODUCT PORTFOLIO
11.12.5 RECENT DEVELOPEMENTS
11.12.5 DATA BRIDGE ANALYSIS
11.13 PROSOLLUS PHARMACEUTICALS
11.13.1 COMPANY OVERVIEW
11.13.2 SWOT ANALYSIS
11.13.3 REVENUE ANALYSIS
11.13.4 PRODUCT PORTFOLIO
11.13.5 RECENT DEVELOPEMENTS
11.13.5 DATA BRIDGE ANALYSIS
11.14 EASTON PHARMACEUTICALS INC.
11.14.1 COMPANY OVERVIEW
11.14.2 SWOT ANALYSIS
11.14.3 REVENUE ANALYSIS
11.14.4 PRODUCT PORTFOLIO
11.14.5 RECENT DEVELOPEMENTS
11.14.5 DATA BRIDGE ANALYSIS
11.15 ANTARES PHARMA, INC.
11.15.1 COMPANY OVERVIEW
11.15.2 SWOT ANALYSIS
11.15.3 REVENUE ANALYSIS
11.15.4 PRODUCT PORTFOLIO
11.15.5 RECENT DEVELOPEMENTS
11.15.5 DATA BRIDGE ANALYSIS
11.16 ENDO PHARMACEUTICALS INC.
11.16.1 COMPANY OVERVIEW
11.16.2 SWOT ANALYSIS
11.16.3 REVENUE ANALYSIS
11.16.4 PRODUCT PORTFOLIO
11.16.5 RECENT DEVELOPEMENTS
11.16.5 DATA BRIDGE ANALYSIS
11.17 TRANSDERMAL TECHNOLOGIES, INC.
11.17.1 COMPANY OVERVIEW
11.17.2 SWOT ANALYSIS
11.17.3 REVENUE ANALYSIS
11.17.4 PRODUCT PORTFOLIO
11.17.5 RECENT DEVELOPEMENTS
11.17.5 DATA BRIDGE ANALYSIS
11.18 SHEFFIELD PHARMACEUTICALS, INC.
11.18.1 COMPANY OVERVIEW
11.18.2 SWOT ANALYSIS
11.18.3 REVENUE ANALYSIS
11.18.4 PRODUCT PORTFOLIO
11.18.5 RECENT DEVELOPEMENTS
11.18.5 DATA BRIDGE ANALYSIS
11.19 SOLVAY
11.19.1 COMPANY OVERVIEW
11.19.2 SWOT ANALYSIS
11.19.3 REVENUE ANALYSIS
11.19.4 PRODUCT PORTFOLIO
11.19.5 RECENT DEVELOPEMENTS
11.19.5 DATA BRIDGE ANALYSIS
11.20 3M DRUG DELIVERY SYSTEMS
11.20.1 COMPANY OVERVIEW
11.20.2 SWOT ANALYSIS
11.20.3 REVENUE ANALYSIS
11.20.4 PRODUCT PORTFOLIO
11.20.5 RECENT DEVELOPEMENTS
11.20.5 DATA BRIDGE ANALYSIS
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
1.1. OVERVIEW OF THE GLOBAL TOPICAL DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL TOPICAL DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. GLOBAL TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
4.3.1.2. GROWTH IN TRANSDERMAL TECHNOLOGY
4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 EXECUTIVE SUMMARY
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
6.2.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.2.1.1. TRANSDERMAL PATCHES
6.2.1.2. TRANSDERMAL GELS
6.2.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.2.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.1.1. SOLUTIONS
6.2.2.1.2. SUSPENSIONS
6.2.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.2.1. GELS
6.2.2.2.2. CREAMS
6.2.2.2.3. OINTMENTS
6.2.2.2.4. PASTES
6.2.2.2.5. LOTIONS
6.2.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.3.1. SUPPOSITORIES
6.2.2.3.2. POWDERS
7 TOPICAL DRUG DELIVERY MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. HOME HEALTHCARE
7.4. CLINICS
7.5. DIAGNOSTIC CENTERS
7.6. OTHERS
8 TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. HOSPITAL PHARMACIES
8.3. PHARMACY STORES
8.4. DIRECT TENDERS
8.5. ONLINE PHARMACY
9 TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.6. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.10. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11 TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES
11.1 JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY)
11.1.1 COMPANY OVERVIEW
11.1.2 SWOT ANALYSIS
11.1.3 REVENUE ANALYSIS
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPEMENTS
11.1.5 DATA BRIDGE ANALYSIS
11.2 CRESCITA THERAPEUTICS
11.2.1 COMPANY OVERVIEW
11.2.2 SWOT ANALYSIS
11.2.3 REVENUE ANALYSIS
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPEMENTS
11.2.5 DATA BRIDGE ANALYSIS
11.3 GALDERMA S.A.
11.3.1 COMPANY OVERVIEW
11.3.2 SWOT ANALYSIS
11.3.3 REVENUE ANALYSIS
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPEMENTS
11.3.5 DATA BRIDGE ANALYSIS
11.4 BIOFARMITALIA S.R.L
11.4.1 COMPANY OVERVIEW
11.4.2 SWOT ANALYSIS
11.4.3 REVENUE ANALYSIS
11.4.4 PRODUCT PORTFOLIO
11.4.5 RECENT DEVELOPEMENTS
11.4.5 DATA BRIDGE ANALYSIS
11.5 PHARMATEK LABORATORIES, INC.
11.5.1 COMPANY OVERVIEW
11.5.2 SWOT ANALYSIS
11.5.3 REVENUE ANALYSIS
11.5.4 PRODUCT PORTFOLIO
11.5.5 RECENT DEVELOPEMENTS
11.5.5 DATA BRIDGE ANALYSIS
11.6 STIEFEL LABORATORIES, INC.
11.6.1 COMPANY OVERVIEW
11.6.2 SWOT ANALYSIS
11.6.3 REVENUE ANALYSIS
11.6.4 PRODUCT PORTFOLIO
11.6.5 RECENT DEVELOPEMENTS
11.6.5 DATA BRIDGE ANALYSIS
11.7 TAPEMARK
11.7.1 COMPANY OVERVIEW
11.7.2 SWOT ANALYSIS
11.7.3 REVENUE ANALYSIS
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPEMENTS
11.7.5 DATA BRIDGE ANALYSIS
11.8 NITTO DENKO CORPORATION
11.8.1 COMPANY OVERVIEW
11.8.2 SWOT ANALYSIS
11.8.3 REVENUE ANALYSIS
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPEMENTS
11.8.5 DATA BRIDGE ANALYSIS
11.9 VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 MYLAN PHARMACEUTICALS INC.
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 HISAMITSU PHARMACEUTICAL CO., INC.
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.10 THERASOLVE NV.
11.10.1 COMPANY OVERVIEW
11.10.2 SWOT ANALYSIS
11.10.3 REVENUE ANALYSIS
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPEMENTS
11.10.5 DATA BRIDGE ANALYSIS
11.11 SAMYANG BIOPHARMACEUTICALS CORPORATION
11.11.1 COMPANY OVERVIEW
11.11.2 SWOT ANALYSIS
11.11.3 REVENUE ANALYSIS
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPEMENTS
11.11.5 DATA BRIDGE ANALYSIS
11.12 LOHMANN THERAPIE-SYSTEME AG
11.12.1 COMPANY OVERVIEW
11.12.2 SWOT ANALYSIS
11.12.3 REVENUE ANALYSIS
11.12.4 PRODUCT PORTFOLIO
11.12.5 RECENT DEVELOPEMENTS
11.12.5 DATA BRIDGE ANALYSIS
11.13 PROSOLLUS PHARMACEUTICALS
11.13.1 COMPANY OVERVIEW
11.13.2 SWOT ANALYSIS
11.13.3 REVENUE ANALYSIS
11.13.4 PRODUCT PORTFOLIO
11.13.5 RECENT DEVELOPEMENTS
11.13.5 DATA BRIDGE ANALYSIS
11.14 EASTON PHARMACEUTICALS INC.
11.14.1 COMPANY OVERVIEW
11.14.2 SWOT ANALYSIS
11.14.3 REVENUE ANALYSIS
11.14.4 PRODUCT PORTFOLIO
11.14.5 RECENT DEVELOPEMENTS
11.14.5 DATA BRIDGE ANALYSIS
11.15 ANTARES PHARMA, INC.
11.15.1 COMPANY OVERVIEW
11.15.2 SWOT ANALYSIS
11.15.3 REVENUE ANALYSIS
11.15.4 PRODUCT PORTFOLIO
11.15.5 RECENT DEVELOPEMENTS
11.15.5 DATA BRIDGE ANALYSIS
11.16 ENDO PHARMACEUTICALS INC.
11.16.1 COMPANY OVERVIEW
11.16.2 SWOT ANALYSIS
11.16.3 REVENUE ANALYSIS
11.16.4 PRODUCT PORTFOLIO
11.16.5 RECENT DEVELOPEMENTS
11.16.5 DATA BRIDGE ANALYSIS
11.17 TRANSDERMAL TECHNOLOGIES, INC.
11.17.1 COMPANY OVERVIEW
11.17.2 SWOT ANALYSIS
11.17.3 REVENUE ANALYSIS
11.17.4 PRODUCT PORTFOLIO
11.17.5 RECENT DEVELOPEMENTS
11.17.5 DATA BRIDGE ANALYSIS
11.18 SHEFFIELD PHARMACEUTICALS, INC.
11.18.1 COMPANY OVERVIEW
11.18.2 SWOT ANALYSIS
11.18.3 REVENUE ANALYSIS
11.18.4 PRODUCT PORTFOLIO
11.18.5 RECENT DEVELOPEMENTS
11.18.5 DATA BRIDGE ANALYSIS
11.19 SOLVAY
11.19.1 COMPANY OVERVIEW
11.19.2 SWOT ANALYSIS
11.19.3 REVENUE ANALYSIS
11.19.4 PRODUCT PORTFOLIO
11.19.5 RECENT DEVELOPEMENTS
11.19.5 DATA BRIDGE ANALYSIS
11.20 3M DRUG DELIVERY SYSTEMS
11.20.1 COMPANY OVERVIEW
11.20.2 SWOT ANALYSIS
11.20.3 REVENUE ANALYSIS
11.20.4 PRODUCT PORTFOLIO
11.20.5 RECENT DEVELOPEMENTS
11.20.5 DATA BRIDGE ANALYSIS
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
